Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
WM Brueckl, JH Ficker, G Zeitler - BMC cancer, 2020 - Springer
Background Immune checkpoint inhibitors (ICI) either alone or in combination with
chemotherapy have expanded our choice of agents for the palliative treatment of non-small …
chemotherapy have expanded our choice of agents for the palliative treatment of non-small …
The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular …
I Tanaka, T Furukawa, M Morise - Cancer Cell International, 2021 - Springer
Comprehensive analysis of omics data, such as genome, transcriptome, proteome,
metabolome, and interactome, is a crucial technique for elucidating the complex mechanism …
metabolome, and interactome, is a crucial technique for elucidating the complex mechanism …
[HTML][HTML] Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
Immune checkpoint inhibitor (ICI) treatment has recently become a first-line therapy for many
non–small cell lung cancer (NSCLC) patients. Unfortunately, most NSCLC patients are …
non–small cell lung cancer (NSCLC) patients. Unfortunately, most NSCLC patients are …
Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells
Y Wang, L Cui, P Georgiev, L Singh, Y Zheng… - …, 2021 - Taylor & Francis
ABSTRACT Prostaglandin E2 (PGE2), an arachidonic acid pathway metabolite produced by
cyclooxygenase (COX)-1/2, has been shown to impair anti-tumor immunity through …
cyclooxygenase (COX)-1/2, has been shown to impair anti-tumor immunity through …
A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy
L Peng, BD Qin, K Xiao, S Xu, JS Yang, YS Zang… - …, 2020 - Taylor & Francis
Background Subgroup analysis of clinical trials of PD-1/PD-L1 inhibitors have reported
ethnic differences in outcomes. We systematically collected published data and performed a …
ethnic differences in outcomes. We systematically collected published data and performed a …
Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types
Background The T cell-inflamed tumor microenvironment, characterized by CD8 T cells and
type I/II interferon transcripts, is an important cancer immunotherapy biomarker. Tumor …
type I/II interferon transcripts, is an important cancer immunotherapy biomarker. Tumor …
Immunotherapeutic advances for NSCLC
M Massafra, MI Passalacqua, V Gebbia… - … : Targets and Therapy, 2021 - Taylor & Francis
Immunotherapy with antibodies against PD-1 or PD-L1, either alone or in combination with
chemotherapy, has revolutionized treatment paradigms of non-small cell lung cancer …
chemotherapy, has revolutionized treatment paradigms of non-small cell lung cancer …
Molecular charcterization of lung adenocarcinoma combining whole exome sequencing, copy number analysis and gene expression profiling
U Testa, E Pelosi, G Castelli - Expert Review of Molecular …, 2022 - Taylor & Francis
Introduction Lung cancer is the leading cause of cancer mortality worldwide; lung
adenocarcinoma (LUAD) corresponds to about 40% of lung cancers. LUAD is a genetically …
adenocarcinoma (LUAD) corresponds to about 40% of lung cancers. LUAD is a genetically …
Resistance mechanism of PD-1/PD-L1 blockade in the cancer-immunity cycle
Y Zhuang, C Liu, J Liu, G Li - OncoTargets and therapy, 2020 - Taylor & Francis
In recent years, the PD-1/PD-L1 axis blockade has become a very promising therapy with
significant clinical benefits for multiple tumor types. However, some patients still do not …
significant clinical benefits for multiple tumor types. However, some patients still do not …
Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy
J Wlosik, S Fattori, P Rochigneux, A Goncalves… - Seminars in …, 2023 - Springer
First-line immunotherapy in non-small-cell lung cancer largely improved patients' survival.
PD-L1 testing is required before immune checkpoint inhibitor initiation. However, this …
PD-L1 testing is required before immune checkpoint inhibitor initiation. However, this …